2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-108621
    RS-25344 hydrochloride
    		Inhibitor 99.93%
    RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects.
    RS-25344 hydrochloride
  • HY-108623
    Atizoram
    		Inhibitor
    Atizoram (CP-80,633), a cyclic nucleotide phosphodiesterase (PDE4) inhibitor, elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice.
    Atizoram
  • HY-90009D
    (6S,12aR)-Tadalafil
    		Inhibitor 99.34%
    (6S,12aR)-Tadalafil (Tadalafil EP Impurity C) is a highly potent PDE5 inhibitor with an IC50 value of 5 nM and has blood pressure lowering activity.
    (6S,12aR)-Tadalafil
  • HY-100118
    BW-A 78U
    		Inhibitor 99.67%
    BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM.
    BW-A 78U
  • HY-115871
    PDE4-IN-4
    		Inhibitor
    PDE4-IN-4 is a dual M3 (pIC50 = 10.2) antagonist-PDE4 (pIC50 = 8.8) inhibitor for the inhaled research of pulmonary diseases.
    PDE4-IN-4
  • HY-106477
    Quazinone
    		Inhibitor 99.7%
    Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .
    Quazinone
  • HY-13927
    Acetildenafil
    		Inhibitor ≥99.0%
    Acetildenafil is a Sildenafil (HY-15025) analogue, a phosphodiesterase 5 (PDE5) inhibitor. Acetildenafil can be isolated from herbal products.
    Acetildenafil
  • HY-121381
    Kuraridine
    		Inhibitor ≥98.0%
    Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC50=0.64 μM).
    Kuraridine
  • HY-108045
    Lodenafil carbonate
    		Inhibitor ≥98.0%
    Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
    Lodenafil carbonate
  • HY-125095
    Yonkenafil hydrochloride
    		Inhibitor 99.43%
    Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil hydrochloride
  • HY-N2284
    Sophoflavescenol
    		Inhibitor 98.78%
    Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC50 of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC50s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.
    Sophoflavescenol
  • HY-145063
    Enpp-1-IN-5
    		Inhibitor 98.16%
    Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1).
    Enpp-1-IN-5
  • HY-106844
    EMD 53998
    		Inhibitor 99.59%
    EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias.
    EMD 53998
  • HY-19929A
    (R)-Tanimilast
    		Inhibitor 99.72%
    (R)-Tanimilast is a isomeride of Tanimilast (HY-19929). Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM).
    (R)-Tanimilast
  • HY-P2867
    Phosphodiesterase II, Bovine Spleen
    Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes.
    Phosphodiesterase II, Bovine Spleen
  • HY-B0715S2
    Pentoxifylline-d5
    		Inhibitor 99.86%
    Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
    Pentoxifylline-d<sub>5</sub>
  • HY-19026
    Siguazodan
    		Inhibitor ≥99.0%
    Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM.
    Siguazodan
  • HY-101705
    Tibenelast sodium
    		Inhibitor 99.66%
    Tibenelast sodium is a phosphodiesterase inhibitor.
    Tibenelast sodium
  • HY-101803
    CP671305
    		Inhibitor 99.95%
    CP671305 is a potent, orally active, selective inhibitor of phosphodiesterase-4-D, and possesses high activities.
    CP671305
  • HY-12085S
    Apremilast-d5
    		Inhibitor 98.63%
    Apremilast-d5 is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].
    Apremilast-d<sub>5</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.